Revised SPC: Mounjaro (tirzepatide) 15mg solution for injection in pre-filled pen
SPC updated with licence extension for use as an adjunct to a reduced-calorie diet and increased physical activity in weight management, and to note it should not be used during pregnancy, and should be discontinued ≥1 month before a planned pregnancy due to its long half-life.
Source:
electronic Medicines compendium
SPS commentary:
Other changes made to the SPC include the addition of the following adverse events: anaphylactic reaction, angioedema, dizziness, hypotension related events, cholecystitis, and hair loss.